A three-dose MVA-BN mpox vaccination series improves the quality of anti-monkeypox virus immunity
Oom, A. L.; Wilson, K. K.; Rettig, S.; Tuen, M.; Samanovic, M. I.; Kottkamp, A. C.; Herati, R. S.; Duerr, R.; Mulligan, M. J.; NYC OSMI Study Group,
Show abstract
The 2022 global outbreak of clade IIb mpox represented a turning point in public healths handling of poxviruses. The primary vaccine available for prevention of mpox is modified vaccinia Ankara from Bavarian-Nordic (MVA-BN). We previously reported a nondurable and low avidity antibody response against mpox elicited by MVA-BN. In this study, we expanded upon this knowledge by employing a microneutralization assay to measure monkeypox virus (MPXV) neutralizing titers and a multiplexed immunoassay to assess IgG titers and avidity against eight MPXV antigens and two vaccinia antigens. Through a machine learning analysis, we uncovered that MVA-BN vaccinees without prior smallpox vaccination largely return to a baseline seroprofile within a year of immunization. Notably, we identified a discrete population within this group that mounted a robust neutralizing antibody response associated with a longer dosing interval during the MVA-BN primary series. Furthermore, we found that boosting with a third dose of MVA-BN increases IgG avidity against certain MPXV antigens, as part of a booster-specific seroprofile. These findings provide critical insights into optimizing immune responses through MVA-BN boosters, presenting a promising approach to addressing the limited MPXV-specific immunity observed following the primary series.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses 95%
- Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses 95%
- Blockade of TGF-β signaling reactivates HIV-1/SIV reservoirs and immune responses in vivo 94%
Similar papers in this journal
- Greater breadth of vaccine-induced immunity in females than males is mediated by increased antibody diversity in germinal center B cells 96%
- Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape over Time 96%
- Structural Mapping of Polyclonal IgG Responses to HA After Influenza Virus Vaccination or Infection 95%
Similar papers in this journal
- SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster 97%
- The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination 96%
- Immune Responses in Fully Vaccinated Individuals Following Breakthrough Infection with the SARS-CoV-2 Delta Variant in Provincetown, Massachusetts 95%
Similar papers in this journal
- Ancestral SARS-CoV-2 driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth 94%
- Post-vaccination SARS-COV-2 among healthcare workers in New Jersey: a genomic epidemiological study 94%
- Neutralising antibodies against the SARS-CoV-2 Delta variant induced by Alhydroxyquim-II-adjuvanted trimeric spike antigens 94%
Similar papers in this journal
- Rapid protection of nonhuman primates against Marburg virus disease using a single low-dose VSV-based vaccine 96%
- Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies 95%
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies. 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.